09/23/2026
Impaired glucose metabolism, insulin resistance, neuroinflammation, and reduced neuronal plasticity have been implicated in depression and other mood disorders. GLP-1 receptor agonists (medications like Ozempic) may help improve these risk factors, which has led to research investigating GLP-1 receptor agonists in psychiatric disorders.
A recent large study analyzed data from a nationwide Swedish database of patients and reported that patients with bipolar disorder who were taking semaglutide (also known as Ozempic or Wegovy) had significantly lower rates of psychiatric hospitalizations compared to times when they were not taking a GLP-1 medication. However, this pattern was not observed with liraglutide and dulaglutide.
Further research using controlled study designs are required to better understand the potential link between GLP-1 receptor agonists and psychiatric outcomes.
🔗 Read more: https://www.sciencedaily.com/releases/2026/09/260907201601.htm
-1
